Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
A systematic review and meta-analysis aggregates clinical outcomes for 145 adult patients with chronic myelomonocytic leukemia treated with venetoclax-based regimens. The figshare admin karger published this supplementary material in April 2026, synthesizing data from 17 publications representing nine unique studies. It reports pooled response rates including a 19.1% complete remission rate and a 71.9% overall response rate.
Primary data format is a DOCX document containing supplementary text and analysis, not a structured data table. License is CC-BY-4.0, requiring attribution.